

## FORM 7

### MONTHLY PROGRESS REPORT

Name of Listed Issuer: Empower Clinics Inc. (the "Issuer").

Trading Symbol: CBDT

Number of Outstanding Listed Securities: 345,510,021

Date: January 7, 2022

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's on going business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

#### **General Instructions**

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

#### **Report on Business**

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer continues to reach a number of important milestones on its path forward, as an integrated healthcare company - serving patients through medical centers, telemedicine platforms, a medical device company, and a high complexity medical diagnostics laboratory.

The Issuer continues to focus on its national clinic expansion strategy. On December 20, 2021 the Issuer has announced the opening of its next The Medi-Collective ("TMC") clinic in Kitchener, ON with co-located Rexall Pharmacy. On December 31, 2021 the Issuer opened its first "The Medi-Collective" in London, Ontario with co-located Guardian Pharmacy.

---

2. Provide a general overview and discussion of the activities of management.

The management remains committed to entirely focusing its corporate priorities and expenditures on its integrated healthcare business.

---

Jennifer Archibald has been appointed Chief Financial Officer of Empower Clinics.

---

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Through its partnership with Fobi AI Inc., the Issuer has launched a premier SMS integration system to enhance Kai Medical Laboratory's ("Kai Labs") existing COVID-19 testing infrastructure. The Company plans to implement the SMS system across its subsidiary network to simplify customer experiences and optimize business operations.

---

The newly developed system was specifically designed to augment Kai Labs COVID-19 testing efforts at the Gala Games Conference in Las Vegas. It utilized QR codes to provide a paperless registration process. Attendees then provided a cellphone number which was subsequently used to conveniently relay their test results via SMS. The message also included follow-up instructions for the attendee to either receive their conference entrance wristband or proceed to secondary screening. The conveniently integrated program with direct message capabilities immensely streamlined the COVID-19 results process.

---

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

The Issuer has successfully completed Health Canada review to sell Covid-19 At-Home Saliva Collection Kit and has received approval from Health Canada to proceed under the original Device Class I authorization for Kai Care COVID-19 At-Home Saliva Collection Kit.

---

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

The Issuer's subsidiary Kai Medical Laboratory was selected as the COVID-19 testing partner for the Gala Games Conference in Las Vegas, Nevada. The Conference was held December 11th-13th, 2021, with the Kai Labs team onsite for more than ten days to provide screening and testing services.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Not applicable

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Not applicable

8. Describe the acquisition of new customers or loss of customers.

Not applicable

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

The Issuer's subsidiary, MediSure Canada, has formally submitted an application to Health Canada for an Interim Order Approval to manufacture and sell MediSure Canada Lateral Flow Rapid COVID-19 Antigen Tests. Approval of this application initiates the commercialization and distribution of its MediSure™ COVID-19 Rapid Antigen Tests in Canada. The Company anticipates a response on the application in early Q1 2022 as Health Canada is continuing to expedite the review of COVID-19 related applications under its Interim Order No. 2.

10. Report on any employee hiring, terminations or lay-offs with details of anticipated length of lay-offs.

New hire: Jennifer Archibald – Chief Financial Officer

11. Report on any labour disputes and resolutions of those disputes if applicable.

Not applicable

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Not applicable

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Not applicable

14. Provide details of any securities issued and options or warrants granted.

<b>Security</b>	<b>Number Issued</b>	<b>Details of Issuance</b>	<b>Use of Proceeds<sup>(1)</sup></b>
Common Shares	125,000	Stock option exercise	\$7,500
Common Shares	31,250	Shares for services	N/A
Stock Options	500,000	Issued to officers, employees	N/A

*(1) The proceeds will primarily be used for working capital purposes.*

15. Provide details of any loans to or by Related Persons.

Not applicable

16. Provide details of any changes in directors, officers, or committee members.

Kyle Appleby – CFO has resigned on Dec 22, 2021

Jennifer Archibald was appointed as CFO of the Company on Dec 22, 2021

17. Discuss any trends, which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The Issuer is relying upon the U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) that approves for sale the COVID-19 Antibody kits of any manufacturers it has selected to use at this time. The FDA EUA has not fully approved certain manufacturers or their specific test kits. Final FDA EUA approval remains pending.

## Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated January 7<sup>th</sup>, 2022

Steven McAuley  
Name of Director or Senior  
Officer

"Steven McAuley"  
Signature  
CEO  
Official Capacity

<b>Issuer Details</b>		For Month End	Date of Report
Name of Issuer Empower Clinics Inc.		December 31, 2021	YY/MM/DD 22/01/07
Issuer Address 4185 Angus Drive			
City/Province/Postal Code Vancouver, BC V6J 4J1		Issuer Fax No. N/A	Issuer Telephone No. 604-789-2146
Contact Name Steven McAuley		Contact Position CEO	Contact Telephone No. 604-789-2146
Contact Email Address s.mcauley@empowerclinics.com		Web Site Address <a href="https://www.empowerclinics.com">https://www.empowerclinics.com</a>	